Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Latest Information Update: 01 Nov 2024
At a glance
- Drugs Catequentinib (Primary) ; Disitamab vedotin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Nov 2024 New trial record